{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-024522","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2026-07-27T20:33:24+00:00","discovered_at":"2026-07-27T20:34:00.416195+00:00","generated_at":"2026-07-27T20:34:17.315386+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GeoVax Q2 net loss $4.4M ($0.97/share); advancing GEO-MVA pivotal study planned Q4 2026","bullets":["Net loss for Q2 2026 was $4.4M ($0.97 per share) vs $5.4M ($8.74 per share) in Q2 2025.","No revenue in Q2 2026 after BARDA contract termination; Q2 2025 had $852K government contract revenue.","Cash $3.1M at June 30, 2026, unchanged from Dec 31, 2025.","Discontinued GEO-CM04S1 COVID-19 vaccine development due to market contraction; no safety concerns.","Planning to initiate pivotal GEO-MVA immunobridging study in Q4 2026 under EMA expedited pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-024522","json":"https://secwatch.observer/filing/0001437749-26-024522.json","markdown":"https://secwatch.observer/filing/0001437749-26-024522.md","text":"https://secwatch.observer/filing/0001437749-26-024522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/0001437749-26-024522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/govx20260727_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T20:34:17.315386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}